December 3, 2018
Published by Engage Therapeutics at December 3, 2018
Categories
On December, 3, 2018, Engage Therapeutics announced at the American Epilepsy Society’s Annual Meeting the successful completion of the open label portion of the StATES (Staccato […]
October 22, 2018
Published by Engage Therapeutics at October 22, 2018
Categories
Engage Therapeutics board member is named one of TIME’s “The Health Care 50” for epilepsy research: Health Care 50 | Time.com
September 14, 2018
Published by Engage Therapeutics at September 14, 2018
Categories
Greg Mayes is the president, CEO, and founder of Engage Therapeutics, founded in 2017 to clinically develop and progress a product called staccato alprazolam, which had […]
September 14, 2018
Published by Engage Therapeutics at September 14, 2018
Categories
“When an aspiring rapper goes viral for all the wrong reasons, he thinks his career is over. But when his best friend gets them into a […]
August 13, 2018
Published by Engage Therapeutics at August 13, 2018
Categories
Read the article by Greg Mayes, Engage Therapeutics CEO, in FACES Annual Newsletter 2018: View the full newsletter here (PDF)
June 27, 2018
Published by Engage Therapeutics at June 27, 2018
Categories
Engage Therapeutics CEO, Greg Mayes, makes opening remarks to Clinical Investigators at the StATES Investigator Meeting. New Orleans, LA – June 8, 2018
May 18, 2018
Published by Engage Therapeutics at May 18, 2018
Categories
G. Mayes CEO, Engage Therapeutics, Summit, NJ, United States Staccato Alprazolam (STAP-001) is a single-use, hand-held, drug-device combination product that provides rapid systemic delivery by inhalation […]
April 30, 2018
Published by Engage Therapeutics at April 30, 2018
Categories
Peachtree BioResearch Solutions to Execute Multi-Center Trial SUMMIT, N.J. – April XX, 2018 – Engage Therapeutics, Inc., today announced dosing of the first patient in its […]
April 20, 2018
Published by Engage Therapeutics at April 20, 2018
Categories
SUMMIT, N.J., Sep. 27, 2017 – Engage Therapeutics, Inc., a clinical-stage biopharmaceutical company developing a new rescue therapy for people who experience uncontrolled epileptic seizures, announced […]